Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Post-Mkt 07-08 17:07:39 EDT

1.69

+0.23

+15.75%

盘后1.63

-0.06-3.55%

17:07 EDT

High1.70	Low1.40	Vol12.45M
Open1.42	D1 Closing1.46	Amplitude20.55%
Mkt Cap270.40M	Tradable Cap229.84M	Total Shares160.00M
T/O20.11M	T/O Rate9.15%	Tradable Shares136.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":1.69,"timestamp":1783540800000,"preClose":1.46,"halted":0,"volume":12448425,"hourTrading":{"tag":"盘后","latestPrice":1.63,"preClose":1.69,"latestTime":"17:07 EDT","volume":52028,"amount":86457.2844684,"timestamp":1783544822909,"change":-0.06,"changeRate":-0.035503,"amplitude":0.035503},"delay":0,"changeRate":0.15753424657534246,"floatShares":136000000,"shares":160000000,"eps":-1.083111,"marketStatus":"Post-Mkt","change":0.23,"latestTime":"07-08 17:07:39 EDT","open":1.42,"high":1.7,"low":1.4,"amount":20110039.706955,"amplitude":0.205479,"askPrice":1.64,"askSize":334,"bidPrice":1.58,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-1.083111,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1783555200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.46,"preHourTrading":{"tag":"盘前","latestPrice":1.42,"preClose":1.46,"latestTime":"09:29 EDT","volume":157742,"amount":220905.367124,"timestamp":1783517353516,"change":-0.04,"changeRate":-0.027397,"amplitude":0.061644},"postHourTrading":{"tag":"盘后","latestPrice":1.63,"preClose":1.69,"latestTime":"17:07 EDT","volume":52028,"amount":86457.2844684,"timestamp":1783544822909,"change":-0.06,"changeRate":-0.035503,"amplitude":0.035503},"volumeRatio":1.946987,"impliedVol":3.0417,"impliedVolPercentile":0.9044},"requestUrl":"/m/hq/s/OTLK/tweets","defaultTab":"tweets","newsList":[{"id":"2648256731","title":"Rocket Pharma Names Joseph Manhede Principal Accounting Officer, Effective July 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2648256731","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648256731?lang=en_us&edition=fundamental","pubTime":"2026-07-01 05:16","pubTimestamp":1782854216,"startTime":"0","endTime":"0","summary":"Rocket Pharma names Joseph Manhede principal accounting officer, effective July 8Rocket Pharmaceuticals said VP of Finance, Senior Controller, Treasurer, Principal Accounting Officer John Militello wi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL2l3GP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRX","BK4139","RCKT","OTLK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647468532","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Outlook Therapeutics (OTLK), Praxis Precision Medicines (PRAX) and Merck & Company (MRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647468532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647468532?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:20","pubTimestamp":1782814820,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Outlook Therapeutics (OTLK), Praxis Precision Medicines (PRAX) an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-outlook-therapeutics-otlk-praxis-precision-medicines-prax-and-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-outlook-therapeutics-otlk-praxis-precision-medicines-prax-and-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0965508806.USD","LU1035773651.USD","LU1037948897.HKD","IE00BLSP4239.USD","LU0266013472.USD","LU1061106388.HKD","LU1057294990.SGD","SG9999014542.SGD","SG9999015358.SGD","LU0320765489.SGD","LU0965509283.SGD","LU1162221912.USD","LU1989772840.SGD","LU0868494617.USD","LU0868494708.USD","IE00BLSP4452.SGD","LU1116320737.USD","IE00BN8TJ469.HKD","LU0477156953.USD","IE00B4R5TH58.HKD","LU1571399168.USD","LU1093756325.SGD","LU1923622614.USD","LU0098860793.USD","LU1430594728.SGD","SG9999013999.USD","LU0211331839.USD","IE00BSNM7G36.USD","LU1066051498.USD","LU0265550359.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU2089984988.USD","LU0130102774.USD","LU0859254822.USD","LU1974910355.USD","LU0203347892.USD","LU2125154935.USD","LU0965509010.AUD","IE00BJJMRZ35.SGD","LU2125154778.USD","PRAX","LU2491050154.USD","LU0980610538.SGD","LU0648001328.SGD","LU0985320562.USD","LU1934455277.USD","SG9999014567.USD","LU1201861249.SGD","LU2468319806.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU1929549753.HKD","SG9999001176.SGD","LU0238689110.USD","OTLK","LU1037948541.HKD","LU0234572021.USD","LU2125909247.SGD","LU1291159041.SGD","SG9999015341.SGD","LU1116320901.HKD","LU2023250843.SGD","LU1066051811.HKD","BK4516","BK4559","LU1941712264.USD","LU1023059063.AUD","SG9999001176.USD","LU2361045086.USD","LU0109394709.USD","LU0265550946.USD","LU2324357040.USD","LU0289739699.SGD","LU0432979614.USD","IE000M9KFDE8.USD","LU0130517989.USD","LU2357627491.SGD","LU2433249047.HKD","LU0006306889.USD","LU2361044949.HKD","LU0122379950.USD","LU2125909593.SGD","MRK","LU0861579265.USD","LU1069347547.HKD","LU0889565916.HKD","IE00BBT3K403.USD","BK4550","BK4588","LU2023250504.SGD","BK4533","SG9999001440.SGD","LU2360032135.SGD","LU0208291251.USD","LU1066053197.SGD","LU0203345920.USD","IE00B1BXHZ80.USD","LU2361044865.SGD","LU2491050071.SGD","LU1585245621.USD","LU2491049909.HKD","SG9999014575.USD","LU1989772923.USD","BK4534","SGXZ57979304.SGD","LU0106261372.USD","SG9999014559.SGD","SG9999002232.USD","LU0965509101.SGD","LU1066051225.USD","LU1093756168.USD","LU2112291526.USD","LU0058720904.USD","LU2106854487.HKD","LU0320765646.SGD","LU0070302665.USD","SG9999002224.SGD","LU0320765992.SGD","IE0002141913.USD","LU1917777945.USD","LU0942090050.USD","LU2461242641.AUD","LU1934455194.USD","BK4139","BK4007","LU1699723380.USD","LU1983299246.USD","BK4585","LU1941712348.USD","LU1989771016.USD","LU1934455863.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647770273","title":"Outlook Therapeutics Regains Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2647770273","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647770273?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:19","pubTimestamp":1782742749,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  said Friday it has regained compliance with Nasdaq's minimum bid price listing requirement.The company said it was notified that it had regained compliance as the closing bid price of its shares had been at $1 per share or greater for 10 consecutive business days.Shares of Outlook Therapeutics were 3.5% lower in Monday trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OTLK","NQmain","BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646393361","title":"Outlook Therapeutics Regains NASDAQ Compliance After Shares Hold Above $1 Bid Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=2646393361","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646393361?lang=en_us&edition=fundamental","pubTime":"2026-06-27 05:31","pubTimestamp":1782509465,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics regains Nasdaq compliance after shares hold above $1 bid thresholdOutlook Therapeutics regained Nasdaq Capital Market compliance with the $1 minimum bid price rule, closing a deli","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL6QBlhJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643635917","title":"Outlook Therapeutics Shares Surge After FDA Accepts Resubmitted Wet AMD Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2643635917","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643635917?lang=en_us&edition=fundamental","pubTime":"2026-06-16 22:20","pubTimestamp":1781619600,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics shares climbed Tuesday after the company said the U.S. Food and Drug Administration accepted its resubmitted biologics license application for ONS-5010/LYTENAVA as a treatment for age-related macular degeneration, a condition in which retina damage results in vision loss.Shares of the biopharmaceutical company were up around 20% at $1.39. The stock has more than quadrupled in the last month.The FDA classified the resubmission as a class 1 review and set a Prescription Drug User Fee Act, or PDUFA, target action date of July 29.If approved, the company said Lytenava would become the first FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration. Outlook Therapeutics said it has begun prelaunch activities ahead of the FDA's decision.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Outlook Therapeutics Shares Surge After FDA Accepts Resubmitted Wet AMD Application","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643681752","title":"BUZZ-Outlook Therapeutics rises after US FDA accepts to review eye disease treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2643681752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643681752?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:21","pubTimestamp":1781612517,"startTime":"0","endTime":"0","summary":"BUZZ-Outlook Therapeutics rises after US FDA accepts to review eye disease treatment** Shares of Outlook Therapeutics OTLK.O rise 8.6% to $1.25 premarket ** Drugmaker says the U.S. FDA has accepted for review its resubmitted marketing application for ONS-5010, branded as Lytenava, after the U.S. FDA declined to approve it in December** OTLK's treatment, Lytenava, targets wet age-related macular degeneration, a common eye disease that causes vision loss due to leaking blood vessels in the retina** The resubmission has been classified as a Class 1 review, with a target action date of July 29, co says** Lytenava is a specific, officially authorized formulation of FDA-approved drug bevacizumab** Up to last close, stock down 26.6% this year  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL4N42O12T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643754762","title":"Outlook Therapeutics says FDA accepts resubmitted Lytentava BLA for wet AMD review","url":"https://stock-news.laohu8.com/highlight/detail?id=2643754762","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643754762?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:03","pubTimestamp":1781611434,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics won FDA acceptance of its resubmitted BLA for ONS-5010/LYTENAVA  to treat wet AMD.FDA set a Class 1 review with a PDUFA target action date of July 29, 2026.Decision could clear the first FDA-approved ophthalmic bevacizumab formulation, supporting standardized manufacturing, labeling, pharmacovigilance.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL5VzcZt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4588","BK4112","IE00BN0W2T93.GBP","OTLK","BK4139","IE00B64PRP62.GBP","SG9999014021.USD","BK4585","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643754474","title":"Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for Ons-5010/Lytenava™ (Bevacizumab-Vikg) as a Treatment for Wet Amd","url":"https://stock-news.laohu8.com/highlight/detail?id=2643754474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643754474?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:02","pubTimestamp":1781611320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUAKYQFM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643754405","title":"Outlook Therapeutics - Pdufa Target Action Date Set for July 29, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643754405","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643754405?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:02","pubTimestamp":1781611320,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUAKYQFM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643754298","title":"Outlook Therapeutics - Initiates Pre-Launch Activities for Ons-5010/Lytenava","url":"https://stock-news.laohu8.com/highlight/detail?id=2643754298","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643754298?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:02","pubTimestamp":1781611320,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUAKYQFM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640182080","title":"Outlook Therapeutics director Yezan Munther Haddadin acquires 29,000 common shares for $24,145.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2640182080","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640182080?lang=en_us&edition=fundamental","pubTime":"2026-06-04 06:03","pubTimestamp":1780524228,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics director Haddadin Yezan Munther bought 29,000 common shares in an open-market purchase.The shares were acquired at USD 0.83 each.Munther’s direct holding rose to 66,167 common shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL3VtC12:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Outlook Therapeutics director Yezan Munther Haddadin acquires 29,000 common shares for $24,145.40","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640957679","title":"Outlook Therapeutics beneficial owner Ghiath M. Sukhtian reports $5 million common share purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2640957679","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640957679?lang=en_us&edition=fundamental","pubTime":"2026-06-02 09:30","pubTimestamp":1780363847,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics director and 10% owner Ghiath M. Sukhtian reported an indirect purchase of 8,539,709 common shares at USD 0.59.Indirect beneficial ownership rose to 22,092,068 common shares.Warrants held indirectly were reset to a USD 0.59 exercise price, covering 15,488,570 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLb19B5v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Outlook Therapeutics beneficial owner Ghiath M. Sukhtian reports $5 million common share purchase","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640295284","title":"Outlook Therapeutics Resubmits Lytenava Biologics License Application to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2640295284","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640295284?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:16","pubTimestamp":1780319781,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  has resubmitted its biologics license application for ONS-5010, or Lytenava, for the treatment of neovascular age-related macular degeneration to the US Food and Drug Administration, the company said Monday.The resubmission comes after the company's successful appeal of the previously announced complete response letter for the drug, where the agency's Office of New Drugs concluded that substantial evidence of effectiveness had been established and no additional trials were required, according to a statement.The decision directed the Division of Ophthalmology and Office of Specialty Medicine to work with the company to reach an agreement on final product labeling, Outlook said.A Prescription Drug User Fee Act date and decision is expected within 60 days of the agency's receipt of the resubmission, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","OTLK","LENZ","BK4585","BK4588","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640095481","title":"Outlook Therapeutics resubmits FDA BLA for Lytneava in wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2640095481","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640095481?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:46","pubTimestamp":1780317982,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics resubmitted its BLA to the FDA for ONS-5010/LYTENAVA  to treat wet age-related macular degeneration.The FDA upheld the company’s appeal of a Complete Response Letter, concluding effectiveness evidence is sufficient, eliminating the need for additional trials.The resubmission was designated Class 1, setting an FDA decision deadline within 60 days of receipt.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL42C9fb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU0314104364.USD","BK4139","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4588","OTLK","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4112","SG9999014005.SGD","NDAQ","LU2210149790.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640954868","title":"Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for Ons-5010/Lytenava™ (Bevacizumab-Vikg)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640954868","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640954868?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:46","pubTimestamp":1780317960,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA5WXSPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640548149","title":"Outlook Therapeutics - FDA Says No Additional Trials Required for Lytenava in Namd","url":"https://stock-news.laohu8.com/highlight/detail?id=2640548149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640548149?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:46","pubTimestamp":1780317960,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA5WXSPG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639691611","title":"Outlook Therapeutics Prices Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2639691611","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639691611?lang=en_us&edition=fundamental","pubTime":"2026-05-29 05:25","pubTimestamp":1780003538,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  said late Thursday it priced a direct offering of over 8.5 million common shares at $0.5855 apiece for gross proceeds of $5 million.The offering is expected to be completed on May 29, subject to closing conditions, according to a statement.Net proceeds will be used for working capital and general corporate purposes, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","OTLK","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639616403","title":"Outlook to sell 8.54M shares at 58.55c in registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2639616403","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639616403?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:08","pubTimestamp":1779998889,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (OTLK) announced that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 8.54M ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-to-sell-8-54m-shares-at-58-55c-in-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-to-sell-8-54m-shares-at-58-55c-in-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639480615","title":"Outlook Therapeutics prices USD 5 million registered direct offering at USD 0.59 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2639480615","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639480615?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:00","pubTimestamp":1779998431,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics priced a registered direct offering of 8,539,709 common shares to GMS Ventures at USD 0.59 per share.Gross proceeds expected at USD 5 million; closing expected on or about May 29, 2026.Net proceeds earmarked for working capital, general corporate purposes.Agreed to reprice warrants for 15,488,570 shares held by GMS; weighted average exercise price cut to USD 0.59 from USD 1.78.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDLxRZZz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823411888.USD","BK4566","LU2095319765.USD","LU0823434740.USD","BK4567","IE00BN0W2T93.GBP","LU0314104364.USD","LU1496350171.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","IE00BKVL7J92.USD","LU1989772923.USD","LU0820562030.AUD","BK4534","IE00B3QW5Z07.USD","LU1778281490.HKD","LU1236620750.USD","LU1093756168.USD","SG9999014039.USD","LU0320765646.SGD","LU0943347566.SGD","LU1551013425.SGD","LU1674673691.USD","LU1162221912.USD","LU1989772840.SGD","LU0238689110.USD","LU2461242641.AUD","OTLK","LU1035775433.USD","LU1496350502.SGD","LU1914381329.SGD","HD","LU2210150020.SGD","BK4550","LU0689472784.USD","BK4588","BK4533","IE00BN0W2V16.EUR","IE00BWXC8680.SGD","LU0820561909.HKD","LU2756315318.SGD","IE00B64PRP62.GBP","NDAQ","LU0098860793.USD","LU2361044865.SGD","LU0823434583.USD","LU2210149790.SGD","BK4083","IE00BSNM7G36.USD","IE00B1XK9C88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639615195","title":"Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2639615195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639615195?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:00","pubTimestamp":1779998400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA39NBLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0818},{"period":"1month","weight":0.8797},{"period":"3month","weight":4.8377},{"period":"6month","weight":1.416},{"period":"1year","weight":-0.2151},{"period":"ytd","weight":-0.0759}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":0.0138},{"period":"3month","weight":0.1061},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.2047},{"period":"ytd","weight":0.0965}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.1402},{"month":3,"riseRate":0.3,"avgChangeRate":-0.095662},{"month":4,"riseRate":0.5,"avgChangeRate":-0.0707},{"month":5,"riseRate":0.7,"avgChangeRate":0.330761},{"month":6,"riseRate":0.4,"avgChangeRate":0.075556},{"month":7,"riseRate":0.545455,"avgChangeRate":0.030861},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}